Pfizer announced discontinuation of a topical acne drug candidate presented at the ACS Fall 2026 meeting, halting development originally linked to fatty liver disease research.
Pfizer reported better-than-expected Q2 earnings driven by Eliquis sales and announced $2.5 billion in cost cuts through 2029. The company aims to offset declining COVID revenue while expanding into t
Polish air traffic controller PANSA faces an 80% income drop after Eurocontrol seized fees to enforce a Belgian court ruling on Pfizer's COVID-19 vaccine contracts. The government promises aid while l
Pfizer executives assert China leads Europe in drug innovation, noting 40% of global oncology trials occur there and more innovative medicines launched in 2024. European stakeholders are now debating
Pfizer CFO Dave Denton steps down August 15 for consumer goods, replaced by interim CFO Cecile Guegan. The company seeks a permanent successor following Denton's tenure overseeing major acquisitions,
Pfizer is reviewing planned investments in Germany following CEO warnings that government drug price cuts threaten long-term predictability. This mirrors similar investment halts by Eli Lilly and Boeh
Several UK law firms are assessing legal claims against Pfizer alleging the contraceptive Depo-Provera causes meningiomas. Parallel litigation exists in the US, while Pfizer defends the drug's establi
ChemBrief